CA
NZ
UK
AU
IND
US
NeoVolta, Inc. filed Definitive Additional Proxy Materials on November 9, 2026, notifying shareholders of five proposals to be voted on at the company's Annual Meeting scheduled for December 22, 2026.
Wintergreen Acquisition Corp. filed a definitive proxy statement on November 9, 2026, calling an Extraordinary General Meeting for November 30, 2026, to seek shareholder approval to extend the company's Business Combination deadline from May 28, 2027 to May 28, 2028, and to eliminate any …
Reviva Pharmaceuticals Holdings, Inc. filed its annual report on Form 10-K for the fiscal year ended December 31, 2025, with the Securities and Exchange Commission on November 9, 2026, disclosing share count, market capitalization, and company classification details.
CKX Lands, Inc. filed soliciting material under Schedule 14A on November 9, 2026, consisting of a transcript of a conference call in which Brad Jacobs announced a $1 billion investment in CKX Lands and outlined progress at QXO.
W. R. Berkley Corporation and its subsidiary Berkley Insurance Company filed a Schedule 13G on November 9, 2026, disclosing beneficial ownership of ordinary shares in Flag Ship Acquisition Corporation as of September 30, 2026.
John C. Malone filed Amendment No. 2 to a Schedule 13D with the SEC on November 9, 2026, disclosing that he ceased to be the beneficial owner of more than five percent of the outstanding common stock of Sirius XM Holdings Inc. as of …
Evo Fund, Evolution Capital Management LLC, and Michael Lerch filed Amendment No. 2 to their Schedule 13D on November 9, 2026, disclosing a partial pre-funded warrant exercise that added 172,797 shares of Super League Enterprise, Inc. common stock on November 5, 2026.
eSports Now, LLC and eSports Holdco LLC filed Amendment No. 1 to Schedule 13D with the SEC on November 9, 2026, disclosing a partial exercise of pre-funded warrants in Super League Enterprise, Inc. on November 5, 2026.
Larimar Therapeutics, Inc. filed a Form 8-K on November 9, 2026, disclosing the completion of its rolling Biologics License Application submission to the U.S. Food and Drug Administration seeking accelerated approval of nomlabofusp for the treatment of patients with Friedreich's ataxia, and reporting a …
Network-1 Technologies, Inc. filed a current report with the SEC on November 9, 2026, disclosing that the company issued a press release on November 5, 2026, announcing its financial results for the three months ended September 30, 2026.
Please wait processing your request...